Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 (THS 2.2)

NCT ID: NCT01967732

Last Updated: 2020-03-17

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

62 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-11-30

Study Completion Date

2014-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this clinical study is to evaluate the pharmacokinetic (PK) profile (rate and amount of nicotine absorbed) following a single use of the THS 2.2 compared to the PK profiles from a single use of a conventional cigarette (CC) and from a single use of nicotine nasal spray (NNS).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Smoking

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

THS 2.2 then CC

Each subject will follow the below study design:

* Day 0 = Wash-out (1 day)
* Day 1 = 1st intervention (single product use of THS 2.2)
* Day 2 = wash-out
* Day 3 = 2nd intervention (single product use of CC).

Group Type ACTIVE_COMPARATOR

THS 2.2

Intervention Type OTHER

Single use of the Tobacco Heating System 2.2 (THS 2.2)

CC

Intervention Type OTHER

Single use of subject's own conventional cigarette (CC)

CC then THS 2.2

Each subject will follow the below study design:

* Day 0 = Wash-out (1 day)
* Day 1 = 1st intervention (single product use of CC)
* Day 2 = wash-out
* Day 3 = 2nd intervention (single product use of THS 2.2).

Group Type ACTIVE_COMPARATOR

THS 2.2

Intervention Type OTHER

Single use of the Tobacco Heating System 2.2 (THS 2.2)

CC

Intervention Type OTHER

Single use of subject's own conventional cigarette (CC)

THS 2.2 then NNS

Each subject will follow the below study design:

* Day 0 = Wash-out (1 day)
* Day 1 = 1st intervention (single product use of THS 2.2)
* Day 2 = wash-out
* Day 3 = 2nd intervention (single administration of NNS)

Group Type ACTIVE_COMPARATOR

THS 2.2

Intervention Type OTHER

Single use of the Tobacco Heating System 2.2 (THS 2.2)

NNS

Intervention Type OTHER

Single administration of 1 mg of nicotine

NNS then THS 2.2

Each subject will follow the below study design:

* Day 0 = Wash-out (1 day)
* Day 1 = 1st intervention (single administration of NNS)
* Day 2 = wash-out
* Day 3 = 2nd intervention (single product use of THS 2.2).

Group Type ACTIVE_COMPARATOR

THS 2.2

Intervention Type OTHER

Single use of the Tobacco Heating System 2.2 (THS 2.2)

NNS

Intervention Type OTHER

Single administration of 1 mg of nicotine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

THS 2.2

Single use of the Tobacco Heating System 2.2 (THS 2.2)

Intervention Type OTHER

CC

Single use of subject's own conventional cigarette (CC)

Intervention Type OTHER

NNS

Single administration of 1 mg of nicotine

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject is Caucasian
* Smoking, healthy subject as judged by the Investigator.
* Subject has smoked at least 10 commercially available non menthol CCs per day (no brand restrictions) for the last 4 weeks.
* Subject has smoked for at least the last 3 consecutive years.
* Subject does not plan to quit smoking in the next 3 months.

Exclusion Criteria

* As per Investigator judgment, the subject cannot participate in the study for any reason (e.g., medical, psychiatric, and/or social reason).
* Subject has received medication within 14 days or within 5 half-lives of a drug (whichever is longer) which has an impact on CYP2A6 activity.
* Female subject is pregnant or breast feeding.
* Female subject does not agree to use an acceptable method of effective contraception.
Minimum Eligible Age

21 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Philip Morris Products S.A.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christelle Haziza, PhD

Role: STUDY_CHAIR

Philip Morris Products S.A.

Adrian Johnston Stewart, MD

Role: PRINCIPAL_INVESTIGATOR

Celerion GB Ltd.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Celerion GB Ltd, 22-24 Lisburn Road

Belfast, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ZRHR-PK-01-EU

Identifier Type: OTHER

Identifier Source: secondary_id

2013-003097-27

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

ZRHR-PK-01-EU

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The Options 2 Study
NCT06595459 RECRUITING PHASE4